Efficiency and safety
in NAT testing
PoET System
PoET® is a whole new system for the detection of viral nucleic acids in blood screening.
High performance PCR kits
Highly sensitive NAT tests for HCV, HBV, HIV, HAV, B19V, HEV and CMV, with WNV for seasonal testing.
Who we are
GFE, established in 2005 by the German Red Cross, rapidly emerged as one of the leading entities in the field of virus detection through nucleic acid amplification technology (NAT). The founders of GFE are esteemed authorities in the realm of blood donation diagnostics, demonstrating a strong dedication to high-caliber research.
Their pivotal contributions during the early 1990’s were instrumental in the advancement of techniques and protocols that integrated NAT testing as a standard practice for screening blood donors in the testing facilities of the German Red Cross.
This innovative endeavor positioned GFE as one of the pioneering organizations globally to enhance blood safety significantly. GFE provides its clientele with NAT tests for all viruses pertinent to transfusions, employing cutting-edge technologies such as multi-dye and target-plexing methodologies, which offer exceptional sensitivity, specificity, and coverage against target mutations.
PoET System – Pushing blood screening forward
This is the future of NAT testing in blood screening. A fully automated instrument, sophisticated software and a series of NAT tests make up this powerful solution for blood screening laboratories. Out of the gate, the PoET® system features highly sensitive NAT tests for HCV, HBV, HIV, HAV, B19V and HEV, with WNV scheduled to follow this spring for seasonal testing. The PoET® Instrument reaches a new level of integration and covers the entire workflow from sample pooling, to sample preparation and PCR testing on a single platform.
Latest News
ISBT 2025 Milan
GFE will be participating in the 35th Regional Congress of the ISBT, taking place May 31 – June 4, 2025 in Milan, Italy. Come and meet our representatives at our Booth No. A45 in the exhibition area to learn more about our PoET® System and new products and...
DGTI 2024
We will be at the 57. Jahrestagung der DGTI together with the 31. Jahrestagung der DGI in Düsseldorf from 11-13 September 2024! See you there? Then visit us at our booth no. 39. Find out more at https://dgti-kongress.de/
GFE launches first CE IVDR-certified assay for nucleic acid amplification technology (NAT) screening of blood donations for cytomegalovirus
PoET® CMV is the first IVD assay on the market to screen donated blood for CMV by nucleic acid amplification technology (NAT) under the IVDR. Screening blood donors with the PoET® CMV test enables pathogen detection and reduces the risk of...